MX2021005462A - Lipidos cationicos que contienen silicio. - Google Patents
Lipidos cationicos que contienen silicio.Info
- Publication number
- MX2021005462A MX2021005462A MX2021005462A MX2021005462A MX2021005462A MX 2021005462 A MX2021005462 A MX 2021005462A MX 2021005462 A MX2021005462 A MX 2021005462A MX 2021005462 A MX2021005462 A MX 2021005462A MX 2021005462 A MX2021005462 A MX 2021005462A
- Authority
- MX
- Mexico
- Prior art keywords
- containing silicon
- cationic lipids
- lipids containing
- methods
- lipid
- Prior art date
Links
- 125000002091 cationic group Chemical group 0.000 title 1
- 229910052710 silicon Inorganic materials 0.000 title 1
- 239000010703 silicon Substances 0.000 title 1
- 150000002632 lipids Chemical class 0.000 abstract 3
- 239000002245 particle Substances 0.000 abstract 3
- -1 cationic lipid Chemical class 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/1888—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of other Si-linkages, e.g. Si-N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862758108P | 2018-11-09 | 2018-11-09 | |
| PCT/US2019/060556 WO2020097520A1 (en) | 2018-11-09 | 2019-11-08 | Cationic lipids containing silicon |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021005462A true MX2021005462A (es) | 2021-08-24 |
Family
ID=70612265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021005462A MX2021005462A (es) | 2018-11-09 | 2019-11-08 | Lipidos cationicos que contienen silicio. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12350383B2 (enExample) |
| EP (1) | EP3877001A4 (enExample) |
| JP (2) | JP2022501064A (enExample) |
| KR (1) | KR20210105888A (enExample) |
| CN (1) | CN113286622A (enExample) |
| AU (1) | AU2019376006B2 (enExample) |
| BR (1) | BR112021008953A2 (enExample) |
| EA (1) | EA202191315A1 (enExample) |
| IL (1) | IL282957A (enExample) |
| MX (1) | MX2021005462A (enExample) |
| SG (1) | SG11202104682PA (enExample) |
| WO (1) | WO2020097520A1 (enExample) |
| ZA (1) | ZA202103229B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108368028B (zh) | 2015-10-28 | 2021-09-03 | 爱康泰生治疗公司 | 用于递送核酸的新型脂质和脂质纳米颗粒制剂 |
| US12678515B2 (en) | 2015-12-30 | 2026-07-14 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| DK3864163T3 (da) | 2018-10-09 | 2024-05-06 | Univ British Columbia | Sammensætninger og systemer omfattende transfektionskompetente vesikler fri for organiske opløsningsmidler og rengøringsmidler og fremgangsmåder forbundet dermed |
| CN112888451A (zh) * | 2018-10-19 | 2021-06-01 | 川斯勒佰尔公司 | 信使rna的无泵包封 |
| CN114729376A (zh) | 2019-09-23 | 2022-07-08 | 欧米茄治疗公司 | 用于调节肝细胞核因子4α(HNF4α)基因表达的组合物和方法 |
| AU2020355000A1 (en) | 2019-09-23 | 2022-03-17 | Sepia Therapeutics, Inc. | Compositions and methods for modulating apolipoprotein B (APOB) gene expression |
| WO2021183720A1 (en) | 2020-03-11 | 2021-09-16 | Omega Therapeutics, Inc. | Compositions and methods for modulating forkhead box p3 (foxp3) gene expression |
| MX2023000511A (es) * | 2020-07-10 | 2023-02-13 | Genevant Sciences Gmbh | Nanoparticulas lipidicas para administrar agentes terapeuticos en los pulmones. |
| CZ310613B6 (cs) | 2020-09-23 | 2026-01-28 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Lipidoidy pro transfekci nukleových kyselin a jejich použití |
| WO2023283359A2 (en) | 2021-07-07 | 2023-01-12 | Omega Therapeutics, Inc. | Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression |
| CZ310443B6 (cs) | 2021-07-19 | 2025-06-25 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití |
| EP4716741A2 (en) | 2023-05-23 | 2026-04-01 | Flagship Labs 114, Inc. | Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression |
| WO2025129128A1 (en) | 2023-12-15 | 2025-06-19 | Vivasor, Inc. | Compositions and methods for non-viral delivery of therapeutic compounds |
| WO2025133951A1 (en) | 2023-12-21 | 2025-06-26 | Genevant Sciences Gmbh | Ionizable lipids suitable for lipid nanoparticles |
| AU2025217182A1 (en) | 2024-02-02 | 2026-08-06 | Editas Medicine, Inc. | MODIFIED GUIDE RNAs |
| WO2025213138A1 (en) | 2024-04-05 | 2025-10-09 | Editas Medicine, Inc. | Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma |
| WO2026022677A1 (en) | 2024-07-22 | 2026-01-29 | Genevant Sciences Gmbh | Permanently charged cationic lipids |
| WO2026022656A2 (en) | 2024-07-22 | 2026-01-29 | Genevant Sciences Gmbh | Lipid particle formulations with permanently charged cationic lipids |
| CN121622610A (zh) * | 2024-09-05 | 2026-03-10 | 苏州慧疗生物医药科技有限公司 | 向细胞内递送遗传物质的三组分脂质纳米颗粒及组合物 |
| WO2026102260A1 (en) | 2024-11-08 | 2026-05-15 | Editas Medicine, Inc. | Crispr-related methods and compositions targeting angiopoietin like 3 (angptl3) |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4618689A (en) | 1985-07-18 | 1986-10-21 | General Electric Company | Novel aminofunctional silicone compositions |
| JPH08166679A (ja) * | 1994-12-13 | 1996-06-25 | Fuji Xerox Co Ltd | 電子写真感光体およびのその製造方法 |
| DE10058620A1 (de) * | 2000-11-25 | 2002-05-29 | Degussa | Verfahren zur Herstellung von Aminoalkylsilanen |
| EP1519714B1 (en) | 2002-06-28 | 2010-10-20 | Protiva Biotherapeutics Inc. | Method and apparatus for producing liposomes |
| AU2004257373B2 (en) | 2003-07-16 | 2011-03-24 | Arbutus Biopharma Corporation | Lipid encapsulated interfering RNA |
| US8895717B2 (en) * | 2005-04-15 | 2014-11-25 | The Board Of Regents Of The University Of Texas System | Delivery of siRNA by neutral lipid compositions |
| US20070292688A1 (en) * | 2005-08-18 | 2007-12-20 | Eastman Kodak Company | Silylamine modified nanoparticulate carriers |
| ITMI20061766A1 (it) * | 2006-09-15 | 2008-03-16 | N P T S R L | Prepolimeri silano-terminati e relativi formulati adesivo-sigillanti |
| EP2279254B1 (en) | 2008-04-15 | 2017-07-05 | Protiva Biotherapeutics Inc. | Novel lipid formulations for nucleic acid delivery |
| AU2009303345B2 (en) * | 2008-10-09 | 2015-08-20 | Arbutus Biopharma Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| ES2472668T3 (es) * | 2009-08-21 | 2014-07-02 | China Petroleum & Chemical Corporation | Componente de catalizador para la polimerizaci�n de etileno, preparación del mismo y catalizador que comprende el componente de catalizador |
| US9006417B2 (en) | 2010-06-30 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
| US9028603B2 (en) * | 2011-06-09 | 2015-05-12 | The Research Foundation Of State University Of New York | Anti-fouling coating compositions and methods for preventing the fouling of surfaces |
| CN105873569B (zh) * | 2013-11-06 | 2020-07-28 | 芝加哥大学 | 用于化疗剂、核酸和光敏剂的递送或共递送的纳米级载体 |
| CN108350455A (zh) * | 2015-07-29 | 2018-07-31 | 阿布特斯生物制药公司 | 用于使b型肝炎病毒基因表达沉默的组合物和方法 |
| CN106834355B (zh) * | 2015-12-07 | 2021-02-23 | 北京大学 | 一种阳离子复合脂质纳米盘及其制备方法和用途 |
| EP3269785A1 (de) * | 2016-07-13 | 2018-01-17 | Nitrochemie Aschau GmbH | Zusammensetzung für silikonkautschukmassen |
| AU2017379901B2 (en) * | 2016-12-21 | 2024-02-15 | Arbutus Biopharma Corporation | Methods for ameliorating infusion reactions |
| WO2019051257A2 (en) * | 2017-09-11 | 2019-03-14 | Arbutus Biopharma Corporation | METHODS OF TREATING HEPATITIS B TYPE INFECTIONS |
| WO2020219941A1 (en) * | 2019-04-26 | 2020-10-29 | Genevant Sciences Gmbh | Lipid nanoparticles |
| MX2023000511A (es) * | 2020-07-10 | 2023-02-13 | Genevant Sciences Gmbh | Nanoparticulas lipidicas para administrar agentes terapeuticos en los pulmones. |
| AU2021403156A1 (en) * | 2020-12-18 | 2023-07-13 | Genevant Sciences Gmbh | Peg lipids and lipid nanoparticles |
-
2019
- 2019-11-08 AU AU2019376006A patent/AU2019376006B2/en active Active
- 2019-11-08 BR BR112021008953-5A patent/BR112021008953A2/pt unknown
- 2019-11-08 MX MX2021005462A patent/MX2021005462A/es unknown
- 2019-11-08 US US17/291,873 patent/US12350383B2/en active Active
- 2019-11-08 JP JP2021525114A patent/JP2022501064A/ja active Pending
- 2019-11-08 EA EA202191315A patent/EA202191315A1/ru unknown
- 2019-11-08 CN CN201980088071.2A patent/CN113286622A/zh active Pending
- 2019-11-08 KR KR1020217017640A patent/KR20210105888A/ko not_active Ceased
- 2019-11-08 WO PCT/US2019/060556 patent/WO2020097520A1/en not_active Ceased
- 2019-11-08 EP EP19881045.9A patent/EP3877001A4/en active Pending
- 2019-11-08 SG SG11202104682PA patent/SG11202104682PA/en unknown
-
2021
- 2021-05-05 IL IL282957A patent/IL282957A/en unknown
- 2021-05-12 ZA ZA2021/03229A patent/ZA202103229B/en unknown
-
2024
- 2024-11-20 JP JP2024202026A patent/JP2025019119A/ja active Pending
-
2025
- 2025-05-27 US US19/219,802 patent/US20250281422A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN113286622A (zh) | 2021-08-20 |
| EP3877001A1 (en) | 2021-09-15 |
| JP2022501064A (ja) | 2022-01-06 |
| BR112021008953A2 (pt) | 2021-08-10 |
| KR20210105888A (ko) | 2021-08-27 |
| WO2020097520A1 (en) | 2020-05-14 |
| ZA202103229B (en) | 2025-08-27 |
| CA3119051A1 (en) | 2020-05-14 |
| NZ776058A (en) | 2025-07-25 |
| AU2019376006A1 (en) | 2021-06-03 |
| EA202191315A1 (ru) | 2021-09-08 |
| US20250281422A1 (en) | 2025-09-11 |
| AU2019376006B2 (en) | 2026-07-02 |
| US20220133636A1 (en) | 2022-05-05 |
| EP3877001A4 (en) | 2022-08-17 |
| IL282957A (en) | 2021-06-30 |
| JP2025019119A (ja) | 2025-02-06 |
| US12350383B2 (en) | 2025-07-08 |
| SG11202104682PA (en) | 2021-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202191315A1 (ru) | Катионные липиды, содержащие кремний | |
| AU2016343803A8 (en) | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids | |
| MA53356A (fr) | Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations | |
| EP1781593A4 (en) | CATIONIC LIPIDS AND USE METHOD | |
| SA516380290B1 (ar) | نواقل لفيروس مرتبط بالغدد لعلاج اضطرابات الاختزان في الجسيمات الحالة | |
| CY1119766T1 (el) | Νεοι ρυθμιστες κινασης βενζοπυρανιου | |
| EA201691448A1 (ru) | Гибридосомы, содержащие их композиции, способы их получения и их применения | |
| MY194902A (en) | Pyrimidine compound | |
| MA47664B1 (fr) | Anticorps anti-c10orf54 et leurs utilisations | |
| MX2017014645A (es) | Profarmacos de alvocidib que tienen una biodisponibilidad aumentada. | |
| CL2021002503A1 (es) | Anticuerpos contra triptasa, composiciones de estos y usos de estos. (divisional de solicitud 201902251) | |
| MX367665B (es) | Formulación mejorada de lípido. | |
| MY184586A (en) | Adenoassociated virus vectors for the treatment of mucopolysaccharidoses | |
| MX2022003907A (es) | Compuestos y composiciones y usos de los mismos. | |
| AU2018277520A1 (en) | 6-5 fused rings as C5a inhibitors | |
| PH12017501539A1 (en) | Disacetoxytubulysin h and analogs thereof | |
| MY172292A (en) | Vectors and sequences for the treatment of diseases | |
| CY1113409T1 (el) | Αναστολεις ακτ και ρ70 s6 κινασης | |
| NZ759295A (en) | 5-5 fused rings as c5a inhibitors | |
| BR112019004911A2 (pt) | oligonucleotídeos modificados e métodos de uso | |
| MX2017002775A (es) | Derivados de pirrolopirimidina como antagonistas del receptor de n-metil-d-aspartato (nmda), subunidad nr2b. | |
| PH12019501893A1 (en) | Methods for increasing blood plasma 2`-deoxyuridine (durd) and thymidylate synthase inhibition | |
| CY1122080T1 (el) | 7-(μορφολινυλ)-2-(n-πιπεραζινυλ) μεθυλοθειαινο [2,3-c]πυριδινης ως αντικαρκινικα φαρμακα | |
| WO2018183631A8 (en) | Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same | |
| MX2021006682A (es) | Inhibidores de descarboxilasa para el tratamiento de la enfermedad de parkinson. |